- Home
- DALN vs CMMB Comparison
DALN vs CMMB Comparison
Compare DALN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- CMMB
- Stock Information
- Founded
- DALN 1954
- CMMB 2004
- Country
- DALN United States
- CMMB Israel
- Employees
- DALN N/A
- CMMB N/A
- Industry
- DALN Newspapers/Magazines
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- CMMB Health Care
- Exchange
- DALN Nasdaq
- CMMB Nasdaq
- Market Cap
- DALN 38.1M
- CMMB 23.0M
- IPO Year
- DALN 2008
- CMMB N/A
- Fundamental
- Price
- DALN $13.63
- CMMB $1.16
- Analyst Decision
- DALN
- CMMB Strong Buy
- Analyst Count
- DALN 0
- CMMB 2
- Target Price
- DALN N/A
- CMMB $8.50
- AVG Volume (30 Days)
- DALN 282.6K
- CMMB 182.0K
- Earning Date
- DALN 07-29-2025
- CMMB 08-20-2025
- Dividend Yield
- DALN N/A
- CMMB N/A
- EPS Growth
- DALN N/A
- CMMB N/A
- EPS
- DALN 5.55
- CMMB N/A
- Revenue
- DALN $123,414,000.00
- CMMB N/A
- Revenue This Year
- DALN N/A
- CMMB N/A
- Revenue Next Year
- DALN N/A
- CMMB N/A
- P/E Ratio
- DALN $2.44
- CMMB N/A
- Revenue Growth
- DALN N/A
- CMMB N/A
- 52 Week Low
- DALN $2.98
- CMMB $0.87
- 52 Week High
- DALN $13.63
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- DALN 94.50
- CMMB 38.60
- Support Level
- DALN $4.16
- CMMB $1.17
- Resistance Level
- DALN $4.69
- CMMB $1.20
- Average True Range (ATR)
- DALN 0.34
- CMMB 0.05
- MACD
- DALN 0.95
- CMMB 0.00
- Stochastic Oscillator
- DALN 100.00
- CMMB 16.46
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.